PRPO Precipio

Precipio & ADS Biotec Launch Seven Beta sites for IV-Cell™

Precipio & ADS Biotec Launch Seven Beta sites for IV-Cell™
EN
06/10/2020

Underlying

PRPOPrecipio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Precipio

 PRESS RELEASE
Free
PRPO PRECIPIO

Precipio Announces Q4 and year-end 2025 Shareholder Update Call

Precipio Announces Q4 and year-end 2025 Shareholder Update Call Conference Call to be held on April 2nd, 2026 at 5:00 PM EST NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  , will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call. Listeners interested in submitting questions in advance should email their...

March 12, 2026 1 EN
 PRESS RELEASE
Free
PRPO PRECIPIO

Precipio Announces Publication of a Joint Study with Memorial Sloan-Ke...

Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoforms NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company   has announced the 1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Cancer Center, demonstrating Precipio’s new Bloodhound assay for Chronic Myeloid Leukemia (CML). According to the...

March 10, 2026 1 EN
 PRESS RELEASE
Free
PRPO PRECIPIO

Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year...

Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M NEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  , announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below are some of the key financial performance metrics for the Company. Revenue Growth – Precipio’s revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over year. Q4-2025 revenues were $6.7M, an ...

February 25, 2026 1 EN
 PRESS RELEASE
Free
PRPO PRECIPIO

Precipio Takes Major Steps Toward a Clean Balance Sheet

Precipio Takes Major Steps Toward a Clean Balance Sheet Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstanding NEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company   has made major strides in cleaning up its balance sheet with two major accomplishments: 1. Major obligation repaid A $1.1 million advance from Change Healthcare (“CHC”), the Company’s clearinghouse service for billing claims processing, has been repaid. CHC experienced a cybersecurity incident in 2024 and advanced Precipio and others funds to cover collection...

January 15, 2026 1 EN
 PRESS RELEASE
Free
PRPO PRECIPIO

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society...

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates clear, positive impacts on patient care NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company   will be presenting at ASH the findings of a joint study conducted with scientific collaborators from in New York, evaluating Precipio’s BCR::ABL1 assay. The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing con...

December 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch